TL;DR: The Centers for Medicare & Medicaid Services modified NCD 161, its cytotoxic food tests coverage policy, effective March 7, 2026. The policy confirms a long-standing exclusion — cytotoxic food tests have not been covered by Medicare since August 5, 1985.


This is one of the oldest coverage exclusions in Medicare's history. NCD 161 is the National Coverage Determination governing the CMS cytotoxic food tests coverage policy. The policy document lists no specific CPT or HCPCS codes, but that absence is itself meaningful — and we'll get into why below.


Quick-Reference Table

Field Detail
Payer CMS
Policy Cytotoxic Food Tests
Policy Code NCD 161
Change Type Modified
Effective Date 2026-03-07
Impact Level Low (for compliant billers) / High (for anyone still billing these tests)
Specialties Affected Allergy, Immunology, Internal Medicine, Integrative Medicine
Key Action Remove any cytotoxic leukocyte food allergy tests from your Medicare charge capture immediately

CMS Cytotoxic Food Tests Coverage Criteria and Medical Necessity Requirements 2026

The Centers for Medicare & Medicaid Services draws a hard line here. Before August 5, 1985, Medicare did cover cytotoxic food tests — but only as an adjunct to in vivo clinical allergy tests in complex food allergy cases. That window closed 40 years ago.

Since August 5, 1985, cytotoxic leukocyte tests for food allergies are excluded from Medicare coverage. The reason stated in the policy: available evidence does not show these tests are safe and effective. CMS published this exclusion in the Federal Register on July 5, 1985.

The medical necessity bar doesn't apply here in the usual sense. Medical necessity criteria exist when a payer wants to define the conditions under which a service is covered. CMS skips that framework entirely for cytotoxic food tests — there are no covered indications, no qualifying diagnoses, and no documentation pathway that gets you to reimbursement. The service is simply not covered.

Prior authorization doesn't apply either. You don't need prior auth for a non-covered service — you just don't bill it to Medicare. That distinction matters for patient communication and financial counseling, not for claims processing.

The 2026 modification to NCD 161 doesn't change the substance of this coverage policy. What it does is confirm that CMS reviewed the policy and kept the exclusion in place. For billing teams, that's the relevant fact.


CMS Cytotoxic Food Tests Exclusions and Non-Covered Indications

This entire service category is excluded. There are no covered subsets, no approved indications, and no exceptions documented in NCD 161.

Cytotoxic leukocyte tests for food allergies — sometimes marketed under brand names or framed as "food sensitivity" testing — fall under this blanket exclusion. The clinical framing doesn't matter. If the test is a cytotoxic food test, Medicare doesn't cover it.

The real risk here is coding drift. Some labs and practices have attempted to bill cytotoxic food tests under broader immunology or allergy codes. That creates claim denial exposure and, depending on the pattern, compliance risk. If you're not sure how your team has been coding these tests, pull a 12-month claims audit before the effective date of March 7, 2026, and review it with your compliance officer.

Practices offering cytotoxic food tests as a cash-pay or out-of-pocket service should ensure they have an Advance Beneficiary Notice (ABN) process in place. Without a properly executed ABN, billing the patient directly for a non-covered service exposes you to liability.


Coverage Indications at a Glance

Indication Status Relevant Codes Notes
Cytotoxic leukocyte tests for food allergies (any indication) Not Covered Not specified in NCD 161 Excluded since August 5, 1985. No qualifying diagnoses exist.
Cytotoxic food tests as adjunct to in vivo allergy testing (pre-August 5, 1985) Historically Covered — No Longer Applicable Not specified Coverage ended with the 1985 CMS Ruling. No current coverage path.

This policy is now in effect (since 2026-03-07). Verify your claims match the updated criteria above.

CMS Cytotoxic Food Tests Billing Guidelines and Action Items 2026

The policy has been modified as of March 7, 2026. Even though the substance hasn't changed, the modification is a signal that CMS reviewed this NCD and kept the exclusion intact. Treat it as a prompt to audit your own practices.

#Action Item
1

Audit your charge capture now. Pull every claim submitted to Medicare in the last 12 months that could overlap with food allergy or food sensitivity testing. Identify any cytotoxic food test billing. If you find it, stop submitting and loop in your compliance officer immediately.

2

Review your superbill and charge master for non-covered services. If any cytotoxic food test codes appear on your superbill — even flagged as "patient responsibility" — make sure the ABN workflow is documented and consistently executed for Medicare patients.

3

Update your front-desk and financial counseling scripts. Medicare patients asking about food allergy testing need to know upfront that cytotoxic food tests are not covered. Document that conversation in the patient record.

+ 3 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

Sample Version Diff Line-by-line changes
Previous VersionCurrent Version
Coverage is considered experimental and investigational for all indicationsCoverage is considered medically necessary when specific criteria are met
Prior authorization is not requiredPrior authorization is required for initial treatment
Documentation must include clinical historyDocumentation must include clinical history
+ 1 more action items

Enter your email to unlock all tables — 100% free

Unlocks every table on this page. Free weekly digest included. By subscribing you agree to our Terms and Privacy Policy.

CPT, HCPCS, and ICD-10 Codes for Cytotoxic Food Tests Under NCD 161

No Codes Specified in NCD 161

The policy does not list specific CPT, HCPCS, or ICD-10 codes. This is unusual and worth understanding.

The absence of codes in NCD 161 reflects the era in which the original policy was written — 1985 — before the current code sets were standardized. CMS excluded the service category by methodology and description, not by specific billing codes.

That creates a practical problem for billing teams. There's no clean code list to block in your charge capture system. The exclusion applies based on what the test does (cytotoxic leukocyte methodology for food allergies), not based on a discrete code. You have to know your tests.

What This Means for Your Claims Edits

You can't simply add a code to a denial edit list and call it done. Instead, your billing team needs to work with your clinical and lab teams to identify which specific tests you perform or order that use cytotoxic leukocyte methodology. Then build the denial edit or billing guideline around the test name and methodology, not a CPT code.

If you use a reference lab for food sensitivity or allergy testing, request their complete test menu and methodology documentation. Flag anything using cytotoxic or leukocyte activation methodology for Medicare exclusion.


Get the Full Picture

Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.

🔍 Search by any code 🔔 Real-time alerts 📊 Line-by-line diffs ⏰ Deadline tracking
Get Full Access → $99/mo · 14-day money-back guarantee